Date |
Product |
Disease |
Phase |
Company |
Therapeutic area |
2016-11-29
|
ORMD-0901 (oral exenatide) |
type 2 diabetes |
1b |
Oramed Pharmaceuticals (Israel) |
Metabolic diseases |
2016-11-29
|
aldoxorubicin |
soft tissue sarcoma |
3 |
CytRx Corporation (USA - CA) |
Cancer - Oncology |
2016-11-28
|
PM01183 (lurbinectidin) |
solid tumors |
1 |
PharmaMar (Spain) |
Cancer - Oncology |
2016-11-28
|
Faslodex® (fulvestrant) |
hormone receptor positive breast cancer |
3 |
AstraZeneca (UK) |
Cancer - Oncology |
2016-11-28
|
GBT440 |
idiopathic pulmonary fibrosis (IPF) |
2a |
Global Blood Therapeutics (USA - CA) |
|
2016-11-28
|
eptinezumab - ALD403 |
chronic migraine |
3 |
Alder Biopharmaceuticals (USA - WA) |
CNS diseases - Neurological diseases |
2016-11-24
|
daprodustat |
anemia associated with chronic kidney disease |
3 |
GSK (UK) |
Kidney diseases - Renal diseases |
2016-11-23
|
JCAR015 - autologous CD3+ T cells transduced with retroviral vector containing a chimeric antigen receptor directed against CD19 (Autologous CD3+ T cells containing CD19 chimeric antigen receptor) |
acute lymphoblastic leukemia (ALL) |
2 |
Juno Therapeutics (USA - WA) |
Cancer - Oncology |
2016-11-22
|
durvalumab (MEDI4736) and tremelimumab |
squamous cell carcinoma of the head and neck |
3 |
AstraZeneca (UK) |
Cancer - Oncology |
2016-11-22
|
TG-1101 (ublituximab) and TGR-1202 |
chronic lymphocytic leukemia (CLL) |
3 |
TG Therapeutics (USA - NY) |
Cancer - Oncology |
2016-11-22
|
filgotinib |
Crohn's disease |
3 |
Gilead Sciences (USA - CA) Galapagos (Belgium) |
Autoimmune diseases - Inflammatory diseases - Digestive diseases |
2016-11-22
|
ABTL0812 (sodium 2-hydroxylinoleate) |
endometrial or squamous lung cancer |
2 |
Ability Pharmaceuticals (Spain) |
Cancer - Oncology |
2016-11-22
|
co.don chondrosphere® (ACT3D-CS) |
cartilage defects of the knee |
2 |
co.don (Germany) |
Bone diseases - Regenerative medicine |
2016-11-21
|
Multikine® (Leukocyte Interleukin, Injection) |
head and neck cancer |
3 |
CEL-SCI Corporation (USA -VA) |
Cancer - Oncology |
2016-11-18
|
biosimilar etanercept |
moderate to severe chronic plaque-type psoriasis |
3 |
Sandoz (Switzerland) |
Autoimmune diseases – Dermatological diseases |
2016-11-18
|
AG-120 - isocitrate dehydrogenase 1 (IDH1)-mutant inhibitor |
isocitrate dehydrogenase-1 (IDH1) mutant positive glioma and chondrosarcoma |
1 |
Agios Pharmaceuticals (USA -MA) |
Cancer - Oncology |
2016-11-18
|
GLPG2737 |
cystic fibrosis |
1 |
Gilead Sciences (USA - CA) |
Rare diseases - Genetic diseases |
2016-11-17
|
NEO-PV-01 and nivolumab |
measurable metastatic melanoma, non-small cell lung cancer, bladder cancer. |
1b |
Neon Therapeutics (USA - MA) |
Cancer - Oncology |
2016-11-17
|
Viaskin rPT® |
reactivation of immunity against Bordetella pertussis (whooping cough) |
1 |
DBV Technologies (France) Geneva University Hospitals (Switzerland) BioNet-Asia (Thailand) |
Infectious diseases |
2016-11-17
|
FR104 |
rheumatoid arthritis, kidney transplantation |
1 |
Effimune (France) now OSE Immunotherapeutics (France) Janssen Biotech, a J&J company (USA - NJ) |
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases - Transplantation |